ImmuCell Corporation Proceeds from Sale of Productive Assets
ImmuCell Corporation (ICCC) reported Proceeds from Sale of Productive Assets of $3.53 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2023-08-10
- ImmuCell Corporation proceeds from sale of productive assets for the quarter ending 2023-06-30 was $3.53M, a 8.51% decline year-over-year.
- ImmuCell Corporation proceeds from sale of productive assets for the quarter ending 2023-03-31 was $3.45M, a 42.55% decline year-over-year.
- ImmuCell Corporation proceeds from sale of productive assets for the quarter ending 2022-12-31 was $3.91M, a 28.16% decline year-over-year.
- ImmuCell Corporation proceeds from sale of productive assets for the quarter ending 2022-09-30 was $4.80M, a 6.88% decline year-over-year.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2023-06-30 | $3.53M 10-Q · filed 2023-08-10 | $6.98M 10-Q · filed 2023-08-10 | $10.89M derived: sum of 3 quarters · filed 2023-08-10 | $15.69M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $3.45M 10-Q · filed 2023-05-11 | $7.36M derived: sum of 2 quarters · filed 2023-08-10 | $12.15M derived: sum of 3 quarters · filed 2023-08-10 | $16.01M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-12-31 | $3.91M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-08-10 | $8.71M derived: sum of 2 quarters · filed 2023-08-10 | $12.57M derived: sum of 3 quarters · filed 2023-08-10 | $18.57M 10-Q · filed 2023-08-10 |
| 2022-09-30 | $4.80M 10-Q · filed 2022-11-21 | $8.66M derived: sum of 2 quarters · filed 2023-08-10 | $14.66M 10-Q · filed 2022-11-21 | $20.10M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-06-30 | $3.86M 10-Q · filed 2023-08-10 | $9.86M 10-Q · filed 2023-08-10 | $15.30M derived: sum of 3 quarters · filed 2023-08-10 | $20.46M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $6.00M 10-Q · filed 2023-05-11 | $11.44M derived: sum of 2 quarters · filed 2023-08-10 | $16.59M derived: sum of 3 quarters · filed 2023-08-10 | $21.14M derived: sum of 4 quarters · filed 2023-08-10 |
| 2021-12-31 | $5.44M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-08-10 | $10.59M derived: sum of 2 quarters · filed 2023-08-10 | $15.14M derived: sum of 3 quarters · filed 2023-08-10 | $19.24M 10-Q · filed 2023-08-10 |
| 2021-09-30 | $5.15M 10-Q · filed 2022-11-21 | $9.69M derived: sum of 2 quarters · filed 2022-11-21 | $13.80M 10-Q · filed 2022-11-21 | $29.14M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-06-30 | $4.54M 10-Q/A · filed 2022-11-21 | $8.65M 10-Q/A · filed 2022-11-21 | $23.99M derived: sum of 3 quarters · filed 2022-11-21 | $23.99M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-03-31 | $4.11M 10-Q/A · filed 2022-11-21 | $19.45M derived: sum of 2 quarters · filed 2022-11-21 | $19.45M derived: sum of 3 quarters · filed 2022-11-21 | |
| 2020-12-31 | $15.34M derived: 10-Q/A 12 month − 10-Q 9 month · filed 2022-11-21 | $15.34M derived: sum of 2 quarters · filed 2022-11-21 | $15.34M 10-Q/A · filed 2022-11-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $600.00 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $600.00 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |